Evidence map›Paper›PMID 1331021›Full record

ArticleIn vitro cellular & developmental biology : journal of the Tissue Culture Association

Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses.

C A Kruse, D H Mitchell, B K Kleinschmidt-DeMasters, W A Franklin, H G Morse, E B Spector, K O Lillehei

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in In vitro cellular & developmental biology : journal of the Tissue Culture Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Adoptive cell therapies for glioblastoma.Frontiers in oncology · 2013
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Immunotherapy of malignant brain tumors.Immunological reviews · 2008
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

C A KruseDepartment of Surgery, University of Colorado Health Sciences Center, Denver 80262.
D H Mitchell
B K Kleinschmidt-DeMasters
W A Franklin
H G Morse
E B Spector
K O Lillehei
University of Colorado Health · US

Funding

IMMUNOTHERAPY FOR PRIMARY BRAIN GLIOMAR01NS028905 · NINDS · UNIVERSITY OF COLORADO DENVER · PI KRUSE, CAROL A · 1990 to 2000
$341k
IMMUNOTHERAPY FOR PRIMARY BRAIN GLIOMAK04NS001401 · NINDS · UNIVERSITY OF COLORADO DENVER · PI KRUSE, CAROL A · 1990 to 1994
–
NINDS NIH HHS KO4 NS01401NINDS NIH HHS R01 NS28905
6 · The paper itself

Abstract

The establishment of a new glioma cell line, DBTRG-05MG, in a modified RPMI 1640 medium is described. The cells were derived from an adult female with glioblastoma multiforme who had been treated with local brain irradiation and multidrug chemotherapy; the tumor showed substantial change in histologic appearance compared to the original biopsy 13 mo. previously. The line has been successfully cryopreserved and passaged up to 20 times. The karyotype of the cells demonstrated it as a hypotetraploid line; the DNA index of 1.9 confirmed the karyotype analyses. By immunocytochemical analysis, the cell line reacted with polyclonal antibodies to vimentin, S100, and neuron specific enolase, reflecting its primitive neuroectodermal character. Positive immunostaining for epidermal growth factor receptor correlated with the excess of chromosome 7 seen in the karyotype. The cell line reacted negatively to antibodies against platelet-derived growth factor and its receptor, neuronal cell adhesion molecule, and glial fibrillary acidic protein. By flow cytometry, the cells were major histocompatibility class I antigen positive and class I antigen negative. Growth kinetic studies demonstrated an approximate population doubling time of 34 to 41 h and a colony forming efficiency of 71.4%. Western blot analysis showed the presence of low levels of normal-sized retinoblastoma protein. When compared to the patient's lymphocyte DNA, no loss of heterozygosity of the p53 tumor suppressor gene was observed in the DBTRG-05MG cell line DNA.

Indexed as

Brain NeoplasmsGenes, p53GlioblastomaTumor Cells, CulturedCell DivisionChromosomes, Human, Pair 7DNA, NeoplasmErbB ReceptorsHumansKaryotypingKineticsMaleMiddle AgedPhosphopyruvate HydrataseS100 ProteinsVimentinDNA, NeoplasmErbB ReceptorsPhosphopyruvate HydrataseS100 ProteinsVimentin

Identifiers

PMID1331021
OpenAlexW1982848659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.